Georgios M.
- Country
- Greece
- Department
- Gastroenterology Clinic
Research Overview
- Long‑Term Safety and Efficacy of SPY001‑001 Monotherapy and Combination Therapy with Long‑Acting Antibodies in Adults with Ulcerative Colitis
- Efficacy and Safety Evaluation of Oral Zasocitinib in Patients with Moderately to Severely Active Crohn's Disease: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety of Oral Zasocitinib in Moderate to Severe Ulcerative Colitis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 165 of 190 partner sites.
Specializations
Inflammatory Bowel Disease Research
This investigator specializes in treating and studying inflammatory bowel diseases, with particular focus on both ulcerative colitis and Crohn's disease.
- Moderate to severe disease states
- Long-term disease management
- Novel therapeutic approaches
The research encompasses innovative oral treatment methods for patients with active disease manifestations.
Ulcerative Colitis Expertise
The investigator focuses on developing treatments for patients with moderately to severely active ulcerative colitis, exploring new therapeutic options for clinical remission.
- Clinical remission assessment
- Treatment efficacy evaluation
- Long-term disease control
Research activities center on innovative oral therapies for achieving sustained disease control.
Crohn's Disease Studies
The investigator conducts research in moderately to severely active Crohn's disease, with particular attention to endoscopic response evaluation.
- Endoscopic response assessment
- Disease activity monitoring
- Treatment optimization
The research focuses on developing effective therapeutic strategies for achieving measurable disease improvement.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.